Recent Advances in Alzheimer’s Disease Treatments with Therapeutic Antibodies to Amyloid-β


  • Jerry Yang Brookline High School
  • Aaron Bradford Bentley University



Alzheimer’s Disease, Therapeutic Antibodies, Amyloid-β, Aducanumab


Alzheimer's disease (AD) is one of the most prevalent and devastating neurodegenerative disorders which affects tens of millions of patients. It imposes significant physical, emotional, and financial burdens on patients, families, and society. Formation of Amyloid-β (Aβ) plaques from the accumulation of Aβ peptides in the cortex and hippocampal region is considered one of the fundamental neuropathological pillars of the disease. Pathological Aβ peptides are generated from its precursor protein through proteolysis. Four small molecule medications were approved by the U. S. Food and Drug Administration (FDA) since 1968 to treat the cognitive symptoms of AD, but they are not curative and have no effect on the development of AD. At least four anti-Aβ antibodies and dozens of other anti-Aβ small molecule agents have been evaluated in clinical trials in the past decades but none of them showed consistent clinical efficacy, presumably because they cannot remove Aβ plaques effectively enough or other reasons such as the patient selection and trial design. Despite the failures, more anti-Aβ antibodies are under development, aiming for more efficient Aβ plaques removal through selectively targeting Aβ oligomers. Among those aducanumab was approved by FDA in 2021 as the first drug to address the underlying biology of AD rather than the symptoms.


Download data is not yet available.

Author Biography

Aaron Bradford, Bentley University

Adjunct Assistant Professor
140 Jennison Hall,
Natural and Applied Science Department
Bentley University
175 Forest Street, Waltham, MA

References or Bibliography

Adair, J. R., Athwal, D. S., Bodmer, M. W., Bright, S. M., Collins, A. M., Pulito, V. L., Rao, P. E., Reedman, R., Rothermel, A. L., Xu, D., & et al. (1994). Humanization of the murine anti-human CD3 monoclonal antibody OKT3. Hum Antibodies Hybridomas, 5(1-2), 41-47.

Alzheimer's Association. (2022). 2022 Alzheimer's disease facts and figures. Alzheimers Dement, 18(4), 700-789.

Armstrong, R. A. (2019). Risk factors for Alzheimer's disease. Folia Neuropathol, 57(2), 87-105.

Bekris, L. M., Yu, C. E., Bird, T. D., & Tsuang, D. W. (2010). Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol, 23(4), 213-227.

Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., Rothe, C., Urban, M., Bardroff, M., Winter, M., Nordstedt, C., & Loetscher, H. (2012). Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis, 28(1), 49-69.

Breijyeh, Z., & Karaman, R. (2020). Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules, 25(24).

Bressler, S. L., Gray, M. D., Sopher, B. L., Hu, Q., Hearn, M. G., Pham, D. G., Dinulos, M. B., Fukuchi, K., Sisodia, S. S., Miller, M. A., Disteche, C. M., & Martin, G. M. (1996). cDNA cloning and chromosome mapping of the human Fe65 gene: interaction of the conserved cytoplasmic domains of the human beta-amyloid precursor protein and its homologues with the mouse Fe65 protein. Hum Mol Genet, 5(10), 1589-1598.

Buss, N. A., Henderson, S. J., McFarlane, M., Shenton, J. M., & de Haan, L. (2012). Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol, 12(5), 615-622.

Cehlar, O., Skrabana, R., Revajova, V., & Novak, M. (2018). Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide. Bratisl Lek Listy, 119(4), 201-204.

Chin, A. L., Negash, S., & Hamilton, R. (2011). Diversity and disparity in dementia: the impact of ethnoracial differences in Alzheimer disease. Alzheimer Dis Assoc Disord, 25(3), 187-195.

Cipriani, G., Dolciotti, C., Picchi, L., & Bonuccelli, U. (2011). Alzheimer and his disease: a brief history. Neurol Sci, 32(2), 275-279.

Cras, P., Kawai, M., Lowery, D., Gonzalez-DeWhitt, P., Greenberg, B., & Perry, G. (1991). Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proc Natl Acad Sci U S A, 88(17), 7552-7556.

Cummings, J., Aisen, P., Lemere, C., Atri, A., Sabbagh, M., & Salloway, S. (2021). Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res Ther, 13(1), 98.

Delpak, A., & Talebi, M. (2020). On the impact of age, gender and educational level on cognitive function in Alzheimer's disease: A quantitative approach. Arch Gerontol Geriatr, 89, 104090.

Demattos, R. B., Lu, J., Tang, Y., Racke, M. M., Delong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., Kinley, R. D., Jordan, W. H., & Hutton, M. L. (2012). A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice. Neuron, 76(5), 908-920.

DeTure, M. A., & Dickson, D. W. (2019). The neuropathological diagnosis of Alzheimer's disease. Mol Neurodegener, 14(1), 32.

Doran, E., Keator, D., Head, E., Phelan, M. J., Kim, R., Totoiu, M., Barrio, J. R., Small, G. W., Potkin, S. G., & Lott, I. T. (2017). Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP. J Alzheimers Dis, 56(2), 459-470.

Esmail, S., & Danter, W. R. (2021). NEUBOrg: Artificially Induced Pluripotent Stem Cell-Derived Brain Organoid to Model and Study Genetics of Alzheimer's Disease Progression. Front Aging Neurosci, 13, 643889.

Fernandez, M. A., Klutkowski, J. A., Freret, T., & Wolfe, M. S. (2014). Alzheimer presenilin-1 mutations dramatically reduce trimming of long amyloid beta-peptides (Abeta) by gamma-secretase to increase 42-to-40-residue Abeta. J Biol Chem, 289(45), 31043-31052.

Fink, H. A., Linskens, E. J., MacDonald, R., Silverman, P. C., McCarten, J. R., Talley, K. M. C., Forte, M. L., Desai, P. J., Nelson, V. A., Miller, M. A., Hemmy, L. S., Brasure, M., Taylor, B. C., Ng, W., Ouellette, J. M., Sheets, K. M., Wilt, T. J., & Butler, M. (2020). Benefits and Harms of Prescription Drugs and Supplements for Treatment of Clinical Alzheimer-Type Dementia. Ann Intern Med, 172(10), 656-668.

Fleisher, A. S., Lowe, S. L., Liu, P., Shcherbinin, S., Li, L., Chua, L., Nakano, M., Hawdon, A., Willis, B. A., Schwarz, A. J., Demattos, R. B., Mintun, M. A., & Irizarry, M. C. (2006). O1‐09‐01: Significant and Sustained Florbetapir F18 Uptake Reduction in Patients with Symptomatic Alzheimer's Disease with Ly3002813, a β‐Amyloid Plaque‐Specific Antibody. Alzheimer's & Dementia, 14(7S_Part_4).

Folch, J., Ettcheto, M., Petrov, D., Abad, S., Pedros, I., Marin, M., Olloquequi, J., & Camins, A. (2018). Review of the advances in treatment for Alzheimer disease: Strategies for combating beta-amyloid protein. Neurologia (Engl Ed), 33(1), 47-58.

Goure, W. F., Krafft, G. A., Jerecic, J., & Hefti, F. (2014). Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics. Alzheimers Res Ther, 6(4), 42.

Haddad, H. W., Malone, G. W., Comardelle, N. J., Degueure, A. E., Poliwoda, S., Kaye, R. J., Murnane, K. S., Kaye, A. M., & Kaye, A. D. (2022). Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer's Disease: A comprehensive review. Health Psychol Res, 10(3), 37023.

Hersi, M., Irvine, B., Gupta, P., Gomes, J., Birkett, N., & Krewski, D. (2017). Risk factors associated with the onset and progression of Alzheimer's disease: A systematic review of the evidence. Neurotoxicology, 61, 143-187.

Hippius, H., & Neundörfer, G. (2022). The discovery of Alzheimer's disease. Dialogues in Clinical Neuroscience, 5(1), 101-108.

Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., Case, M., Dean, R. A., Hake, A., Sundell, K., Poole Hoffmann, V., Carlson, C., Khanna, R., Mintun, M., DeMattos, R., Selzler, K. J., & Siemers, E. (2018). Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. N Engl J Med, 378(4), 321-330.

Horder, H., Johansson, L., Guo, X., Grimby, G., Kern, S., Ostling, S., & Skoog, I. (2018). Midlife cardiovascular fitness and dementia: A 44-year longitudinal population study in women. Neurology, 90(15), e1298-e1305.

Husna Ibrahim, N., Yahaya, M. F., Mohamed, W., Teoh, S. L., Hui, C. K., & Kumar, J. (2020). Pharmacotherapy of Alzheimer's Disease: Seeking Clarity in a Time of Uncertainty. Front Pharmacol, 11, 261.

Ivanoiu, A., Pariente, J., Booth, K., Lobello, K., Luscan, G., Hua, L., Lucas, P., Styren, S., Yang, L., Li, D., Black, R. S., Brashear, H. R., & McRae, T. (2016). Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies. Alzheimers Res Ther, 8(1), 24.

Jeremic, D., Jimenez-Diaz, L., & Navarro-Lopez, J. D. (2021). Past, present and future of therapeutic strategies against amyloid-beta peptides in Alzheimer's disease: a systematic review. Ageing Res Rev, 72, 101496.

Karran, E., & De Strooper, B. (2022). The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov, 21(4), 306-318.

Ketter, N., Brashear, H. R., Bogert, J., Di, J., Miaux, Y., Gass, A., Purcell, D. D., Barkhof, F., & Arrighi, H. M. (2017). Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients. J Alzheimers Dis, 57(2), 557-573.

Kinoshita, A., Whelan, C. M., Smith, C. J., Berezovska, O., & Hyman, B. T. (2002). Direct visualization of the gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein: association with Fe65 and translocation to the nucleus. J Neurochem, 82(4), 839-847.

Kwak, K. A., Lee, S. P., Yang, J. Y., & Park, Y. S. (2018). Current Perspectives regarding Stem Cell-Based Therapy for Alzheimer's Disease. Stem Cells Int, 2018, 6392986.

Kwan, P., Konno, H., Chan, K. Y., & Baum, L. (2020). Rationale for the development of an Alzheimer's disease vaccine. Hum Vaccin Immunother, 16(3), 645-653.

Lautenschlager, N. T., Cox, K. L., Flicker, L., Foster, J. K., van Bockxmeer, F. M., Xiao, J., Greenop, K. R., & Almeida, O. P. (2008). Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA, 300(9), 1027-1037.

Lesne, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006). A specific amyloid-beta protein assembly in the brain impairs memory. Nature, 440(7082), 352-357.

Li, Z., Shue, F., Zhao, N., Shinohara, M., & Bu, G. (2020). APOE2: protective mechanism and therapeutic implications for Alzheimer's disease. Mol Neurodegener, 15(1), 63.

Liu, E., Schmidt, M. E., Margolin, R., Sperling, R., Koeppe, R., Mason, N. S., Klunk, W. E., Mathis, C. A., Salloway, S., Fox, N. C., Hill, D. L., Les, A. S., Collins, P., Gregg, K. M., Di, J., Lu, Y., Tudor, I. C., Wyman, B. T., Booth, K., Broome, S., Yuen, E., Grundman, M., Brashear, H. R., Bapineuzumab, & Clinical Trial, I. (2015). Amyloid-beta 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology, 85(8), 692-700.

Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., Costafreda, S. G., Dias, A., Fox, N., Gitlin, L. N., Howard, R., Kales, H. C., Kivimäki, M., Larson, E. B., Ogunniyi, A., Orgeta, V., Ritchie, K., Rockwood, K., Sampson, E. L., Samus, Q., Schneider, L. S., Selbæk, G., Teri, L., & Mukadam, N. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet, 396(10248), 413-446.

Logovinsky, V., Satlin, A., Lai, R., Swanson, C., Kaplow, J., Osswald, G., Basun, H., & Lannfelt, L. (2016). Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Abeta antibody. Alzheimers Res Ther, 8(1), 14.

Mantile, F., & Prisco, A. (2020). Vaccination against beta-Amyloid as a Strategy for the Prevention of Alzheimer's Disease. Biology (Basel), 9(12).

Mayeux, R., & Stern, Y. (2012). Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med, 2(8).

Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., Apostolova, L. G., Salloway, S. P., & Skovronsky, D. M. (2021). Donanemab in Early Alzheimer's Disease. N Engl J Med, 384(18), 1691-1704.

Miyoshi, I., Fujimoto, Y., Yamada, M., Abe, S., Zhao, Q., Cronenberger, C., Togo, K., Ishibashi, T., Bednar, M. M., Kupiec, J. W., & Binneman, B. (2013). Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study. Int J Clin Pharmacol Ther, 51(12), 911-923.

Mucke, L., & Selkoe, D. J. (2012). Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med, 2(7), a006338.

Musiek, E. S., & Bennett, D. A. (2021). Aducanumab and the "post-amyloid" era of Alzheimer research? Neuron, 109(19), 3045-3047.

Nelson, P. T., Head, E., Schmitt, F. A., Davis, P. R., Neltner, J. H., Jicha, G. A., Abner, E. L., Smith, C. D., Van Eldik, L. J., Kryscio, R. J., & Scheff, S. W. (2011). Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol, 121(5), 571-587.

Ostrowitzki, S., Lasser, R. A., Dorflinger, E., Scheltens, P., Barkhof, F., Nikolcheva, T., Ashford, E., Retout, S., Hofmann, C., Delmar, P., Klein, G., Andjelkovic, M., Dubois, B., Boada, M., Blennow, K., Santarelli, L., Fontoura, P., & Investigators, S. C. R. (2017). A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimers Res Ther, 9(1), 95.

Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019). A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease. Nat Rev Neurol, 15(2), 73-88.

Penney, J., Ralvenius, W. T., & Tsai, L. H. (2020). Modeling Alzheimer's disease with iPSC-derived brain cells. Mol Psychiatry, 25(1), 148-167.

Piller, C. (2022). Blots on a field? Science, 377(6604), 358-363.

Plotkin, S. S., & Cashman, N. R. (2020). Passive immunotherapies targeting Abeta and tau in Alzheimer's disease. Neurobiol Dis, 144, 105010.

Rajan, K. B., Weuve, J., Barnes, L. L., McAninch, E. A., Wilson, R. S., & Evans, D. A. (2021). Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060). Alzheimers Dement, 17(12), 1966-1975.

Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. C., Liu, E., Grundman, M., Yuen, E., Black, R., Brashear, H. R., Bapineuzumab, & Clinical Trial, I. (2014). Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med, 370(4), 322-333.

Salwa, & Kumar, L. (2021). Engrafted stem cell therapy for Alzheimer's disease: A promising treatment strategy with clinical outcome. J Control Release, 338, 837-857.

Scarmeas, N., Luchsinger, J. A., Schupf, N., Brickman, A. M., Cosentino, S., Tang, M. X., & Stern, Y. (2009). Physical activity, diet, and risk of Alzheimer disease. JAMA, 302(6), 627-637.

Se Thoe, E., Fauzi, A., Tang, Y. Q., Chamyuang, S., & Chia, A. Y. Y. (2021). A review on advances of treatment modalities for Alzheimer's disease. Life Sci, 276, 119129.

Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med, 8(6), 595-608.

Sengupta, U., Nilson, A. N., & Kayed, R. (2016). The Role of Amyloid-beta Oligomers in Toxicity, Propagation, and Immunotherapy. EBioMedicine, 6, 42-49.

Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021). APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. The Lancet Neurology, 20(1), 68-80.

Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011). Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med, 1(1), a006189.

Sevigny, J., Chiao, P., Bussiere, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O'Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M. S., Quintero-Monzon, O., Scannevin, R. H., Arnold, H. M., Engber, T., Rhodes, K., Ferrero, J., Hang, Y., Mikulskis, A., Grimm, J., Hock, C., Nitsch, R. M., & Sandrock, A. (2016). The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature, 537(7618), 50-56.

Silva, M. V. F., Loures, C. M. G., Alves, L. C. V., de Souza, L. C., Borges, K. B. G., & Carvalho, M. D. G. (2019). Alzheimer's disease: risk factors and potentially protective measures. J Biomed Sci, 26(1), 33.

Singh, S., Kumar, N. K., Dwiwedi, P., Charan, J., Kaur, R., Sidhu, P., & Chugh, V. K. (2018). Monoclonal Antibodies: A Review. Curr Clin Pharmacol, 13(2), 85-99.

Spires-Jones, T. L., & Hyman, B. T. (2014). The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron, 82(4), 756-771.

Steinbrook, R. (2021). The Accelerated Approval of Aducanumab for Treatment of Patients With Alzheimer Disease. JAMA Intern Med, 181(10), 1281.

Suzuki, K., Iwata, A., & Iwatsubo, T. (2017). The past, present, and future of disease-modifying therapies for Alzheimer's disease. Proc Jpn Acad Ser B Phys Biol Sci, 93(10), 757-771.

Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., Reyderman, L., Berry, D. A., Berry, S., Gordon, R., Kramer, L. D., & Cummings, J. L. (2021). A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther, 13(1), 80.

Urayama, A., Moreno-Gonzalez, I., Morales-Scheihing, D., Kharat, V., Pritzkow, S., & Soto, C. (2022). Preventive and therapeutic reduction of amyloid deposition and behavioral impairments in a model of Alzheimer's disease by whole blood exchange. Mol Psychiatry.

van Dyck, C. H. (2018). Anti-Amyloid-beta Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise. Biol Psychiatry, 83(4), 311-319.

Vandenberghe, R., Rinne, J. O., Boada, M., Katayama, S., Scheltens, P., Vellas, B., Tuchman, M., Gass, A., Fiebach, J. B., Hill, D., Lobello, K., Li, D., McRae, T., Lucas, P., Evans, I., Booth, K., Luscan, G., Wyman, B. T., Hua, L., Yang, L., Brashear, H. R., Black, R. S., Bapineuzumab, & Clinical Study, I. (2016). Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Alzheimers Res Ther, 8(1), 18.

Ward, M. W., Concannon, C. G., Whyte, J., Walsh, C. M., Corley, B., & Prehn, J. H. (2010). The amyloid precursor protein intracellular domain(AICD) disrupts actin dynamics and mitochondrial bioenergetics. J Neurochem, 113(1), 275-284.

Wilde, M. I., & Goa, K. L. (1996). Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs, 51(5), 865-894.

Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L., Fisher, E. M., & Strydom, A. (2015). A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci, 16(9), 564-574.

Wolfe, M. S. (2020). Substrate recognition and processing by gamma-secretase. Biochim Biophys Acta Biomembr, 1862(1), 183016.



How to Cite

Yang, J., & Bradford, A. (2022). Recent Advances in Alzheimer’s Disease Treatments with Therapeutic Antibodies to Amyloid-β. Journal of Student Research, 11(3).



HS Review Articles